-
1
-
-
57349164272
-
Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2
-
Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK and Bast RC Jr: Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 7: 3747-3758, 2008.
-
(2008)
Cell Cycle
, vol.7
, pp. 3747-3758
-
-
Le, X.F.1
Mao, W.2
Lu, C.3
Thornton, A.4
Heymach, J.V.5
Sood, A.K.6
Bast Jr., R.C.7
-
2
-
-
34548071359
-
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network
-
DOI 10.1158/1078-0432.CCR-07-0701
-
Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA and Arteaga CL: Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909-4919, 2007. (Pubitemid 47294799)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.16
, pp. 4909-4919
-
-
Ritter, C.A.1
Perez-Torres, M.2
Rinehart, C.3
Guix, M.4
Dugger, T.5
Engelman, J.A.6
Arteaga, C.L.7
-
3
-
-
2542526069
-
kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells
-
DOI 10.1158/0008-5472.CAN-03-3900
-
Nahta R, Takahashi T, Ueno NT, Hung MC and Esteva FJ: P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64: 3981-3986, 2004. (Pubitemid 38697313)
-
(2004)
Cancer Research
, vol.64
, Issue.11
, pp. 3981-3986
-
-
Nahta, R.1
Takahashi, T.2
Ueno, N.T.3
Hung, M.-C.4
Esteva, F.J.5
-
4
-
-
78649732997
-
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
-
Guarneri V, Barbieri E, Dieci MV, Piacentini F and Conte P: Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev 3: 62-66, 2010.
-
(2010)
Cancer Treat Rev
, vol.3
, pp. 62-66
-
-
Guarneri, V.1
Barbieri, E.2
Dieci, M.V.3
Piacentini, F.4
Conte, P.5
-
5
-
-
75149145066
-
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort
-
Gianni L, Eiermann W, Semiglazov V, et al: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375: 377-384, 2010.
-
(2010)
Lancet
, vol.375
, pp. 377-384
-
-
Gianni, L.1
Eiermann, W.2
Semiglazov, V.3
-
6
-
-
78649390831
-
Treatment of HER2-overexpressing breast cancer
-
Baselga J: Treatment of HER2-overexpressing breast cancer. Ann Oncol 21: 36-40, 2010.
-
(2010)
Ann Oncol
, vol.21
, pp. 36-40
-
-
Baselga, J.1
-
7
-
-
73949128107
-
Histone deacetylase inhibitors in cancer therapy
-
Lane AA and Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468, 2009.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5459-5468
-
-
Lane, A.A.1
Chabner, B.A.2
-
8
-
-
77956413585
-
Regulation of apoptosis-associated genes by histone deacetylase inhibitors: Implications in cancer therapy
-
Jazirehi AR: Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anticancer Reagents 21: 805-813, 2010.
-
(2010)
Anticancer Reagents
, vol.21
, pp. 805-813
-
-
Jazirehi, A.R.1
-
9
-
-
78149472680
-
Optimizing the management of Her2-positive early breast cancer: The clinical reality
-
Verma S, Lavasani S, Mackey J, et al: Optimizing the management of Her2-positive early breast cancer: the clinical reality. Curr Oncol 17: 20-33, 2010.
-
(2010)
Curr Oncol
, vol.17
, pp. 20-33
-
-
Verma, S.1
Lavasani, S.2
Mackey, J.3
-
10
-
-
0033996361
-
ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency
-
DOI 10.1128/MCB.20.9.3210-3223.2000
-
Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM and Hynes NE: ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 20: 3210-3223, 2000. (Pubitemid 30215033)
-
(2000)
Molecular and Cellular Biology
, vol.20
, Issue.9
, pp. 3210-3223
-
-
Lane, H.A.1
Beuvink, I.2
Motoyama, A.B.3
Daly, J.M.4
Neve, R.M.5
Hynes, N.E.6
-
11
-
-
12544250381
-
Genes affecting the cell cycle, growth, maintenance, and reagent sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling
-
Le XF, Lammayot A, Gold D, et al: Genes affecting the cell cycle, growth, maintenance, and reagent sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 280: 2092-2104, 2005.
-
(2005)
J Biol Chem
, vol.280
, pp. 2092-2104
-
-
Le, X.F.1
Lammayot, A.2
Gold, D.3
-
12
-
-
77149165788
-
Sodium butyrate increases expression of the coxsackie and adenovirus receptor in colon cancer cells
-
Küster K, Grötzinger C, Koschel A, Fischer A, Wiedenmann B and Anders M: Sodium butyrate increases expression of the coxsackie and adenovirus receptor in colon cancer cells. Cancer Invest 28: 268-274, 2010.
-
(2010)
Cancer Invest
, vol.28
, pp. 268-274
-
-
Küster, K.1
Grötzinger, C.2
Koschel, A.3
Fischer, A.4
Wiedenmann, B.5
Anders, M.6
-
13
-
-
35848945096
-
Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines
-
DOI 10.1158/1535-7163.MCT-07-0079
-
Emlet DR, Brown KA, Kociban DL, Pollice AA, Smith CA, Ong BB and Shackney SE: Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther 6: 2664-2674, 2007. (Pubitemid 350058147)
-
(2007)
Molecular Cancer Therapeutics
, vol.6
, Issue.10
, pp. 2664-2674
-
-
Emlet, D.R.1
Brown, K.A.2
Kociban, D.L.3
Pollice, A.A.4
Smith, C.A.5
Ong, B.B.L.6
Shackney, S.E.7
-
14
-
-
0038555374
-
Short-chain fatty acid inhibitors of histone deacetylases: Promising anticancer therapeutics?
-
DOI 10.2174/1568009033481994
-
Chen JS, Faller DV and Spanjaard RA: Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr Cancer Reagent Targets 3: 219-236, 2003. (Pubitemid 36565763)
-
(2003)
Current Cancer Drug Targets
, vol.3
, Issue.3
, pp. 219-236
-
-
Chen, J.S.1
Faller, D.V.2
Spanjaard, R.A.3
-
15
-
-
50249175241
-
Will histone deacetylase inhibitors require combination with other agents to fulfill their therapeutic potential?
-
Nolan L, Johnson PW, Ganesan A, Packham G and Crabb SJ: Will histone deacetylase inhibitors require combination with other agents to fulfill their therapeutic potential? Br J Cancer 99: 689-694, 2008.
-
(2008)
Br J Cancer
, vol.99
, pp. 689-694
-
-
Nolan, L.1
Johnson, P.W.2
Ganesan, A.3
Packham, G.4
Crabb, S.J.5
-
16
-
-
1642490813
-
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B
-
Fuino L, Bali P, Wittmann S, et al: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2: 971-984, 2003.
-
(2003)
Mol Cancer Ther
, vol.2
, pp. 971-984
-
-
Fuino, L.1
Bali, P.2
Wittmann, S.3
-
17
-
-
78650321835
-
Novel chimeric histone deacetylase inhibitors: A series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity
-
Mahboobi S, Sellmer A, Winkler M, et al: Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity. J Med Chem 53: 8546-8555, 2010.
-
(2010)
J Med Chem
, vol.53
, pp. 8546-8555
-
-
Mahboobi, S.1
Sellmer, A.2
Winkler, M.3
-
18
-
-
0028176483
-
Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
-
Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66, 1994.
-
(1994)
Cell
, vol.78
, pp. 59-66
-
-
Polyak, K.1
Lee, M.H.2
Erdjument-Bromage, H.3
Koff, A.4
Roberts, J.M.5
Tempst, P.6
Massagué, J.7
-
20
-
-
77953952433
-
Kip1 as a prognostic factor in breast cancer: A systematic review and meta-analysis
-
Kip1 as a prognostic factor in breast cancer: a systematic review and meta-analysis. J Cell Mol Med 14: 944-953, 2010.
-
(2010)
J Cell Mol Med
, vol.14
, pp. 944-953
-
-
Guan, X.1
Wang, Y.2
Xie, R.3
-
21
-
-
33644883611
-
Histone deacetylase inhibitor apicidin induces cyclin e expression through Sp1 sites
-
Kim S, Kang JK, Kim YK, et al: Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sites. Biochem Biophys Res Commun 342: 1168-1173, 2006.
-
(2006)
Biochem Biophys Res Commun
, vol.342
, pp. 1168-1173
-
-
Kim, S.1
Kang, J.K.2
Kim, Y.K.3
-
22
-
-
34848871701
-
The histone deacetylase inhibitor trichostatin A mediates upregulation of 5-lipoxygenase promoter activity by recruitment of Sp1 to distinct GC-boxes
-
DOI 10.1016/j.bbalip.2007.08.003, PII S1388198107001722
-
Schnur N, Seuter S, Katryniok C, Rådmark O and Steinhilber D: The histone deacetylase inhibitor trichostatin A mediates upregulation of 5-lipoxygenase promoter activity by recruitment of Sp1 to distinct GC-boxes. Biochim Biophys Acta 1771: 1271-1282, 2007. (Pubitemid 47499235)
-
(2007)
Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
, vol.1771
, Issue.10
, pp. 1271-1282
-
-
Schnur, N.1
Seuter, S.2
Katryniok, C.3
Radmark, O.4
Steinhilber, D.5
-
23
-
-
77953248068
-
HDAC4 inhibits the transcriptional activation of mda-7/IL-24 induced by Sp1
-
Pan L, Pan H, Jiang H, Du J, Wang X, Huang B and Lu J: HDAC4 inhibits the transcriptional activation of mda-7/IL-24 induced by Sp1. Cell Mol Immunol 7: 221-226, 2010.
-
(2010)
Cell Mol Immunol
, vol.7
, pp. 221-226
-
-
Pan, L.1
Pan, H.2
Jiang, H.3
Du, J.4
Wang, X.5
Huang, B.6
Lu, J.7
-
24
-
-
39749099976
-
The histone deacetylase inhibitor trichostatin A induces GADD45gamma expression via Oct and NF-Y binding sites
-
DOI 10.1038/sj.onc.1210735, PII 1210735
-
Campanero MR, Herrero A and Calvo V: The histone deacetylase inhibitor trichostatin A induces GADD45 gamma expression via Oct and NF-Y binding sites. Oncogene 27: 1263-1272, 2008. (Pubitemid 351294685)
-
(2008)
Oncogene
, vol.27
, Issue.9
, pp. 1263-1272
-
-
Campanero, M.R.1
Herrero, A.2
Calvo, V.3
-
25
-
-
33746338907
-
1/S arrest induced by histone deacetylase inhibitor sodium butyrate in E1A + Ras-transformed cells is mediated through down-regulation of E2F activity and stabilization of beta-catenin
-
1/S arrest induced by histone deacetylase inhibitor sodium butyrate in E1A + Ras-transformed cells is mediated through down-regulation of E2F activity and stabilization of beta-catenin. J Biol Chem 281: 21040-21051, 2006.
-
(2006)
J Biol Chem
, vol.281
, pp. 21040-21051
-
-
Abramova, M.V.1
Pospelova, T.V.2
Nikulenkov, F.P.3
Hollander, C.M.4
Fornace Jr., A.J.5
Pospelov, V.A.6
-
26
-
-
78149468828
-
Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects
-
Marshall GM, Gherardi S, Xu N, et al: Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 29: 5957-5968, 2010.
-
(2010)
Oncogene
, vol.29
, pp. 5957-5968
-
-
Marshall, G.M.1
Gherardi, S.2
Xu, N.3
-
27
-
-
52949120373
-
Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells
-
Domingo-Domènech J, Pippa R, Tαpia M, Gascón P, Bachs O and Bosch M: Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat 112: 53-62, 2008.
-
(2008)
Breast Cancer Res Treat
, vol.112
, pp. 53-62
-
-
Domingo-Domènech, J.1
Pippa, R.2
Tapia, M.3
Gascón, P.4
Bachs, O.5
Bosch, M.6
-
28
-
-
60749098440
-
Kip1 gene transcription by mitogens
-
Kip1 gene transcription by mitogens. Cell Cycle 8: 115-124, 2009.
-
(2009)
Cell Cycle
, vol.8
, pp. 115-124
-
-
Bagui, T.K.1
Cui, D.2
Roy, S.3
Mohapatra, S.4
Shor, A.C.5
Ma, L.6
Pledger, W.J.7
-
29
-
-
0034637527
-
Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27
-
DOI 10.1074/jbc.C000147200
-
Yang HY, Zhou BP, Hung MC and Lee MH: Oncogenic signals of HER2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem 275: 24735-24739, 2000. (Pubitemid 30626576)
-
(2000)
Journal of Biological Chemistry
, vol.275
, Issue.32
, pp. 24735-24739
-
-
Yang, H.-Y.1
Zhou, B.P.2
Hung, M.-C.3
Lee, M.-H.4
-
30
-
-
42549093548
-
Jab1 is overexpressed in human breast cancer and is a downstream target for HER2/neu
-
Hsu MC, Chai CY, Hou MF, Chang HC, Chen WT and Hung WC: Jab1 is overexpressed in human breast cancer and is a downstream target for HER2/neu. Mod Pathol 21: 609-616, 2008.
-
(2008)
Mod Pathol
, vol.21
, pp. 609-616
-
-
Hsu, M.C.1
Chai, C.Y.2
Hou, M.F.3
Chang, H.C.4
Chen, W.T.5
Hung, W.C.6
|